MMDA-2
From Wikipedia, the free encyclopedia
 | |
|---|---|
| Systematic (IUPAC) name | |
| 1-(6-methoxy-1,3-benzodioxol-5-yl)propan-2-amine | |
| Clinical data | |
| Legal status | Uncontrolled (but may be covered under the Federal Analogue Act in the United States and under similar bills in other countries) |
| Routes | Oral, Insufflated, Rectal |
| Identifiers | |
| CAS number | 23693-18-7 |
| ATC code | None |
| PubChem | CID 90966 |
| ChemSpider | 82147 |
| Chemical data | |
| Formula | C11H15NO3 |
| Mol. mass | 209.24 g/mol |
| SMILES
| |
MMDA-2 (2-methoxy-4,5-methylenedioxyamphetamine) is a psychedelic drug of the amphetamine class.[1] It is closely related to MMDA and MDA.[1]
Alexander Shulgin was likely the first to synthesize MMDA-2.[1] In his book PiHKAL, the dose is listed as 25–50 mg, and the duration is listed as 8–12 hours.[1] Shulgin reports that MMDA-2 produces effects such as enhanced awareness, empathy, and visual facilitation and distortion, as well as some side effects like gastrointestinal upset and appetite loss.[1] He states that 30 mg is very similar to 80 mg of MDA, and also remarks that it would be impossible for anyone to have a bad experience on the drug at that dose.[1]
Scientific research has shown that MMDA-2, unlike MMDA, but similarly to 6-methyl-MDA, is only very weak at inducing the release of serotonin or dopamine,[2] and accordingly, does not produce amphetamine-appropriate responding in animals in drug discrimination studies.[3] Instead, MMDA-2 is likely to act as a pure 5-HT2 receptor agonist similarly to the DOx series of compounds, with activation of the 5-HT2A receptor conferring its psychedelic effects.[4]
MMDA-2 has been sold as a designer drug in Japan.[5]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Ann Shulgin; Alexander Shulgin (1991). Pihkal: A Chemical Love Story. Transform Press. ISBN 0-9630096-0-5.
- ↑ McKenna DJ, Guan XM, Shulgin AT (March 1991). "3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine". Pharmacology, Biochemistry, and Behavior 38 (3): 505–12. doi:10.1016/0091-3057(91)90005-M. PMID 1829838.
- ↑ Glennon RA, Yousif M, Naiman N, Kalix P (March 1987). "Methcathinone: a new and potent amphetamine-like agent". Pharmacology, Biochemistry, and Behavior 26 (3): 547–51. doi:10.1016/0091-3057(87)90164-X. PMID 3575369.
- ↑ Clare BW (2002). "QSAR of benzene derivatives: comparison of classical descriptors, quantum theoretic parameters and flip regression, exemplified by phenylalkylamine hallucinogens". Journal of Computer-aided Molecular Design 16 (8–9): 611–33. doi:10.1023/A:1021966231380. PMID 12602954.
- ↑ Min JZ, Shimizu Y, Toyo'oka T, Inagaki S, Kikura-Hanajiri R, Goda Y (October 2008). "Simultaneous determination of 11 designated hallucinogenic phenethylamines by ultra-fast liquid chromatography with fluorescence detection". Journal of Chromatography B 873 (2): 187–94. doi:10.1016/j.jchromb.2008.08.020. PMID 18789774.
External links
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| |||||
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.